@article {1519,
	title = {Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model.},
	journal = {The Journal of allergy and clinical immunology},
	volume = {120},
	year = {2007},
	month = {2007 Nov},
	pages = {1146-52},
	abstract = {Omalizumab (trade name Xolair) is approved by the US Food and Drug Administration for treatment of moderate-to-severe allergic asthma. Given the high acquisition cost of omalizumab, its role and cost-effectiveness in disease management require definition.},
	keywords = {Anti-Allergic Agents, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Asthma, Cost-Benefit Analysis, Humans, Models, Theoretical, Severity of Illness Index},
	issn = {1097-6825},
	doi = {10.1111/j.1524-4733.2010.00763.x},
	author = {Wu, Ann C and Paltiel, A David and Kuntz, Karen M and Weiss, Scott T and Fuhlbrigge, Anne L}
}
